PowerUp Acquisition Corp. agrees to pay sponsor $1M fee upon closing of Aspire Biopharma deal

Aspire Biopharma Holdings, Inc.

Sponsor SRIRAMA Associates to receive $1M modified promissory note fee upon successful closing of Aspire Biopharma business combination.
Original $2M fee from terminated Visiox BCA replaced by this $1M fee.
Fee included as Purchaser Expenses in the Aspire BCA dated August 26, 2024.
Agreement dated October 2, 2024 between SPAC and Sponsor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.